echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > GUT: Not to be underestimated!

    GUT: Not to be underestimated!

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gastric cancer (GC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths.
    The high mortality rate is mainly due to the late manifestations of the disease.
    More than 70% of countries report that the ratio of GC mortality to morbidity is very high (>0.
    8).

    Gastric cancer (GC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths.
    Gastric cancer (GC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths.
    Stomach cancer

    However, in the world, only Japan and South Korea currently have government-sponsored endoscopy screening projects.
    A research report pointed out that the
    internal diameter screening reduces the mortality and morbidity of GC across the country (0.
    43 and 0.
    35 respectively), highlighting the benefits of universal endoscopic screening for early detection of GC.

    Screening diameter screening reduces the mortality and morbidity of GC across the country (0.
    43 and 0.
    35, respectively), highlighting the benefits of universal endoscopic screening for early detection of GC.
    Internal diameter screening is a reduction in the national mortality and morbidity of GC (0.
    43 and 0.
    35, respectively), highlighting the benefits of universal endoscopic screening for early detection of GC.

    In countries with a moderate or low incidence of GC, the method of universal endoscopic screening is not cost-effective.
    For such areas, targeted endoscopic screening of high-risk groups may be a better approach.

    For such areas, targeted endoscopic screening of high-risk groups may be a better approach.
    For such areas, targeted endoscopic screening of high-risk groups may be a better approach.

    Generally, a series of identifiable precancerous stages of intestinal cancer subtypes develop-inflammation, atrophy, intestinal deformation (IM), dysplasia and subsequent canceration.
    -However, the clinical adoption rate of monitoring for gastric precancerous lesions is still very low.
    This is mainly due to the lack of supporting clinical evidence from large-scale prospective studies, inconsistent sampling and reporting methods, and the cost of implementing population-level screening.

    Multiple studies have shown that the gastritis assessment (OLGA) associated with gastric cancer can reliably identify subgroups of patients at high risk of GC.
    In order to investigate the incidence of gastric cancer (GC) attributable to gastrointestinal metaplasia (IM), and to verify that OLGIM conducts targeted endoscopic monitoring in low- and medium-incidence areas of GC, experts from the National University of Singapore conducted relevant research.
    The results Published in GUT magazine.

    Multiple studies have shown that the gastritis assessment (OLGA) associated with gastric cancer can reliably identify subgroups of patients at high risk of GC.
    Multiple studies have shown that the gastritis assessment (OLGA) associated with gastric cancer can reliably identify subgroups of patients at high risk of GC.

    The researchers conducted a prospective, longitudinal and multicenter study in Singapore.
    Participants in the study included 2980 patients who underwent screening gastroscopy with standardized gastric mucosal sampling from 2004.
    01 to 2010.
    12.
    Regular monitoring endoscopy was performed in the 3rd and 5th years.
    Participants were also matched with the missed diagnosis of early gastric tumors (EGN) from the National Disease Registry.

    (A) Age-adjusted incidence of EGN, stratified by OLGIM stage.
    (B) The block diagram depicts the time (years) of the onset of EGN in patients with OLGIM II (orange) and OLGIM III-IV (red)

    (A) Age-adjusted incidence of EGN, stratified by OLGIM stage.
    (B) The block diagram depicts the time (years) of the onset of EGN in patients with OLGIM II (orange) and OLGIM III-IV (red)

    A total of 21 participants were diagnosed with EGN.
    In general,
    IM is an important risk factor for EGN, which can increase the risk of EGN by 4.
    36 times (HR=5.
    36; 95%CI: 1.
    51-19.
    0; P<0.
    01).
    The age-adjusted EGN incidence rates for patients with and without IM were 133.
    9 per 100,000 person-years and 12.
    5 per 100,000 person-years.

    Diagnosis of IM is an important risk factor for EGN, which can increase the risk of EGN by 4.
    36 times (HR=5.
    36; 95%CI: 1.
    51-19.
    0; P<0.
    01).
    IM is an important risk factor for EGN, which can increase the risk of EGN by 4.
    36 times (HR=5.
    36; 95%CI: 1.
    51-19.
    0; P<0.
    01).

    Among them, the participants of OLGIMIII-IV stage had the greatest risk, which increased almost 20 times (HR=20.
    7; 95%CI: 5.
    04-85.
    6; P<0.
    01).
    More than half of EGNs (n=4/7) were attributed to patients with baseline OLGIM stage III-IV onset within 2 years (range: 12.
    7-44.
    8 months).

    Among them, the participants of OLGIMIII-IV stage had the greatest risk, which increased almost 20 times (HR=20.
    7; 95%CI: 5.
    04-85.
    6; P<0.
    01).
    More than half of EGNs (n=4/7) were attributed to patients with baseline OLGIM stage III-IV onset within 2 years (range: 12.
    7-44.
    8 months).
    Among them, the participants of OLGIMIII-IV stage had the greatest risk, which increased almost 20 times (HR=20.
    7; 95%CI: 5.
    04-85.
    6; P<0.
    01).
    More than half of EGNs (n=4/7) were attributed to patients with baseline OLGIM stage III-IV onset within 2 years (range: 12.
    7-44.
    8 months).

    At the same time, researchers found that if Helicobacter pylori is negative, serum trefoil factor 3 (TFF3) can distinguish OLGIM III-IV patients.
    Participants with OLGIM II also had a significant risk of EGN (HR=7.
    34; 95%CI: 1.
    60-33.
    7; P=0.
    02).
    In addition, a significant history of smoking will further increase the risk of EGN in OLGIM stage II-IV patients.

    If Helicobacter pylori is negative, serum trefoil factor 3 (TFF3) can distinguish OLGIM III-IV patients.
    If Helicobacter pylori is negative, serum trefoil factor 3 (TFF3) can distinguish OLGIM III-IV patients.

    In summary, the study recommends the use of risk stratification methods, while endoscopic monitoring for high-risk patients (OLGIM III-IV) within 2 years, and endoscopic monitoring for moderate-risk patients (OLGIM II) within 5 years.
    Good prediction of gastric cancer.

    Endoscopic monitoring for high-risk patients (OLGIM III-IV) within 2 years, and endoscopic monitoring for moderate-risk patients (OLGIM II) within 5 years to better predict the occurrence of gastric cancer.
    Endoscopic monitoring for high-risk patients (OLGIM III-IV) within 2 years, and endoscopic monitoring for moderate-risk patients (OLGIM II) within 5 years to better predict the occurrence of gastric cancer.

     

    references:

    Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
    http://dx.
    doi.
    org/10.
    1136/gutjnl-2021-324057

    Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.